Incomplete Presentations in Typical Chronic Inflammatory Demyelinating Polyneuropathy: A Single-Center, Retrospective Study. [PDF]
Min YG +3 more
europepmc +1 more source
Serum glycobiomarkers for chronic inflammatory demyelinating polyneuropathy. [PDF]
Furukawa S +12 more
europepmc +1 more source
Feasibility of Outpatient Transforaminal Lumbar Interbody Fusion (TLIF) in Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. [PDF]
Coimbra M +4 more
europepmc +1 more source
Impact of Social Deprivation on Diagnosis, Management and Outcome of Chronic Inflammatory Demyelinating Polyneuropathy at a Tertiary UK Centre. [PDF]
Rajabally Z +4 more
europepmc +1 more source
Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study. [PDF]
Di L +7 more
europepmc +1 more source
Hereditary Neuropathy with Liability to Pressure Palsies Mimicking a Chronic Inflammatory Demyelinating Polyneuropathy Variant: A Case Report Highlighting Diagnostic Challenges. [PDF]
Yamamoto M, Hatanaka Y, Kaida K.
europepmc +1 more source
Related searches:
Chronic Inflammatory Demyelinating Polyneuropathy
New England Journal of Medicine, 2005Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disease of the peripheral nervous system with a prevalence of 1-2/100,000. Clinical and experimental findings suggest a role of immune pathomechanisms;however, the target antigens are still unknown.
Hans-Peter Hartung +2 more
exaly +4 more sources
Treatment of chronic inflammatory demyelinating polyneuropathy
Muscle & Nerve, 2022AbstractChronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic peripheral polyneuropathy that results in disability through immune‐mediated nerve injury, but which not uncommonly has residual and irreversible neurological deficits after the active inflammatory component of the disorder has been treated.
Jeffrey A. Allen, Richard A. Lewis
openaire +2 more sources

